摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-amino-1-(2-chloro-4-fluorophenyl)-1H-pyrazole-4-carbonitrile | 1159678-22-4

中文名称
——
中文别名
——
英文名称
5-amino-1-(2-chloro-4-fluorophenyl)-1H-pyrazole-4-carbonitrile
英文别名
5-amino-1-(2-chloro-4-fluorophenyl)pyrazole-4-carbonitrile
5-amino-1-(2-chloro-4-fluorophenyl)-1H-pyrazole-4-carbonitrile化学式
CAS
1159678-22-4
化学式
C10H6ClFN4
mdl
——
分子量
236.636
InChiKey
JCIVMNINUMETIZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    67.6
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为产物:
    描述:
    2-氯-4-氟苯肼盐酸盐二氯甲烷sodium hydroxide乙氧基亚甲基丙二腈 、 Brine 、 magnesium sulfate 作用下, 以 甲醇 为溶剂, 反应 4.0h, 以to provide 5-amino-1-(2-chloro-4-fluorophenyl)-1H-pyrazole-4-carbonitrile (28.9 g)的产率得到5-amino-1-(2-chloro-4-fluorophenyl)-1H-pyrazole-4-carbonitrile
    参考文献:
    名称:
    THERAPEUTIC AGENTS 414
    摘要:
    化合物式(I)的复合物在治疗或预防通过葡萄糖激酶(GLK或GK)介导的疾病或医疗状况中非常有用,从而导致胰岛素分泌的葡萄糖阈值降低。
    公开号:
    US20100093757A1
点击查看最新优质反应信息

文献信息

  • [EN] 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS FOR THE TEATMENT OF CNS DISORDERS<br/>[FR] DÉRIVÉS DE 1,5-DIHYDRO-PYRAZOLO(3,4-D)PYRIMIDIN-4-ONE ET LEUR UTILISATION EN TANT QUE MODULATEURS DE PDE9A POUR LE TRAITEMENT DE TROUBLES DU SNC
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2009068617A1
    公开(公告)日:2009-06-04
    The invention relates to novel substituted pyrazolopyrimidines. Chemically, the compounds are characterised by general Formula (I): with R1 being phenyl or pyridyl, any of which is substituted with 1 to 4, preferably 1 to 3 substituents X; X independently of each other being selected from C2-C6-alky1 or Ci-C6-alkoxy, where C2-C6-alkyl and C1-C6-alkoxy are at least dihalogenated up to perhalogenated. preferably with 2 to 6 halogen substituents, and the halogen atoms being selected from the group of fluoro, chloro and bromo, preferably fluoro; R2 being phenyl or heteroaryl, where phenyl is substituted by 1 to 3 radicals and heteroaryl is optionally substituted by 1 to 3 radicals in each case independently of one another selected from the group of C1-C6-alkyI, C1-C6- alkoxy, hydroxycarbonyl, cyano, trifluoromethyl, amino, nitro, hydroxy, C1-C6- alkylamino, halogen, C6-C10-arylcarbonylamino, C1-C6-alkylcarbonylamino, C1- C6-alkylaminocarbonyl. C1-C6-alkoxycarbonyl, C6-C10-arylaminocarbonyl, heteroarylaminocarbonyl. heteroarylcarbonylamino, C1-C6-alkylsulphonyl- amino, C1-C6-alkylsulphonyl and C1-C6-alkylthio; The new compounds shall be used for the manufacture of medicaments, in particular medicaments for improving, perception, concentration, learning and/or memory in patients in need thereof.
    该发明涉及新型取代吡唑嘧啶化合物。从化学角度来看,这些化合物的特征由一般式(I)表示:其中R1为苯基或吡啶基,其中任一取代为1到4个,优选为1到3个取代基X;X独立地选自C2-C6-烷基或C1-C6-烷氧基,其中C2-C6-烷基和C1-C6-烷氧基至少经过二卤化至全卤化处理,最好具有2到6个卤素取代基,卤素原子选自,最好为;R2为苯基或杂环烷基,其中苯基取代为1到3个基团,杂环烷基可选择性地取代为1到3个基团,每种基团独立地选自C1-C6-烷基、C1-C6-烷氧基、羟基羰基、基、三甲基、基、硝基、羟基、C1-C6-烷基基、卤素、C6-C10-芳基羰胺基、C1-C6-烷基羰胺基、C1-C6-烷基羰基、C1-C6-烷氧羰基、C6-C10-芳基基羰基、杂环烷基基羰基、杂环烷基羰胺基、C1-C6-烷基磺酰基、C1-C6-烷基磺酰基和C1-C6-烷基基;这些新化合物可用于制备药物,特别是用于改善患者的感知、注意力、学习和/或记忆的药物。
  • Therapeutic agents
    申请人:Astrazeneca AB
    公开号:US08143263B2
    公开(公告)日:2012-03-27
    A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.
    公式(I)的化合物可用于治疗或预防通过葡萄糖激酶(GLK或GK)介导的疾病或医疗状况,从而导致胰岛素分泌的葡萄糖阈值降低。
  • 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS
    申请人:Eickmeier Christian
    公开号:US20110015193A1
    公开(公告)日:2011-01-20
    The invention relates to novel substituted pyrazolopyrimidines. Chemically, the compounds are characterised by general Formula (I): with R 1 being phenyl or pyridyl, any of which is substituted with 1 to 4, preferably 1 to 3 substituents X; X independently of each other being selected from C 2 -C 6 -alky 1 or Ci-C 6 -alkoxy, where C 2 -C 6 -alkyl and C 1 -C 6 -alkoxy are at least dihalogenated up to perhalogenated. preferably with 2 to 6 halogen substituents, and the halogen atoms being selected from the group of fluoro, chloro and bromo, preferably fluoro; R 2 being phenyl or heteroaryl, where phenyl is substituted by 1 to 3 radicals and heteroaryl is optionally substituted by 1 to 3 radicals in each case independently of one another selected from the group of C 1 -C 6 -alkyI, C 1 -C 6 -alkoxy, hydroxycarbonyl, cyano, trifluoromethyl, amino, nitro, hydroxy, C 1 -C 6 -alkylamino, halogen, C 6 -C 10 -arylcarbonylamino, C 1 -C 6 -alkylcarbonylamino, C 1 -C 6 -alkylaminocarbonyl. C 1 -C 6 -alkoxycarbonyl, C 6 -C 10 -arylaminocarbonyl, heteroarylaminocarbonyl. heteroarylcarbonylamino, C 1 -C 6 -alkylsulphonyl-amino, C 1 -C 6 -alkylsulphonyl and C 1 -C 6 -alkylthio; The new compounds shall be used for the manufacture of medicaments, in particular medicaments for improving, perception, concentration, learning and/or memory in patients in need thereof.
  • US8143263B2
    申请人:——
    公开号:US8143263B2
    公开(公告)日:2012-03-27
  • US8648085B2
    申请人:——
    公开号:US8648085B2
    公开(公告)日:2014-02-11
查看更多